Literature DB >> 31059617

Why are there no approved treatments for cognitive impairment in schizophrenia?

Richard S E Keefe1.   

Abstract

Entities:  

Year:  2019        PMID： 31059617      PMCID： PMC6502426          DOI： 10.1002/wps.20648

Source DB:  PubMed          Journal:  World Psychiatry        ISSN： 1723-8617            Impact factor:   49.548


× No keyword cloud information.
  5 in total

1.  Placebo Response and Practice Effects in Schizophrenia Cognition Trials.

Authors:  Richard S E Keefe; Vicki G Davis; Philip D Harvey; Alexandra S Atkins; George M Haig; Owen Hagino; Stephen Marder; Dana C Hilt; Daniel Umbricht
Journal:  JAMA Psychiatry       Date:  2017-08-01       Impact factor: 21.596

2.  The MATRICS consensus cognitive battery: what we know 6 years later.

Authors:  Michael F Green; Josette G Harris; Keith H Nuechterlein
Journal:  Am J Psychiatry       Date:  2014-11-01       Impact factor: 18.112

3.  Cognition and motivation as treatment targets in schizophrenia.

Authors:  Richard S E Keefe
Journal:  JAMA Psychiatry       Date:  2014-09       Impact factor: 21.596

4.  Nonsocial and social cognition in schizophrenia: current evidence and future directions.

Authors:  Michael F Green; William P Horan; Junghee Lee
Journal:  World Psychiatry       Date:  2019-06       Impact factor: 49.548

5.  Schizophrenia is a cognitive illness: time for a change in focus.

Authors:  René S Kahn; Richard S E Keefe
Journal:  JAMA Psychiatry       Date:  2013-10       Impact factor: 21.596
  5 in total
  11 in total

1.  Long-Term Benzodiazepine Prescription During Maintenance Therapy of Individuals With Psychosis Spectrum Disorders-Associations With Cognition and Global Functioning.

Authors:  Bojana Savić; Stefan Jerotić; Ivan Ristić; Mirjana Zebić; Nikolina Jovanović; Manuela Russo; Nadja P Marić
Journal:  Clin Neuropharmacol       Date:  2021 May-Jun 01       Impact factor: 1.592

Review 2.  Gender Differences in Clinical and Psychosocial Features Among Persons With Schizophrenia: A Mini Review.

Authors:  Giulia Maria Giordano; Paola Bucci; Armida Mucci; Pasquale Pezzella; Silvana Galderisi
Journal:  Front Psychiatry       Date:  2021-12-22       Impact factor: 4.157

3.  Recognition of Electroencephalography-Related Features of Neuronal Network Organization in Patients With Schizophrenia Using the Generalized Choquet Integrals.

Authors:  Małgorzata Plechawska-Wójcik; Paweł Karczmarek; Paweł Krukow; Monika Kaczorowska; Mikhail Tokovarov; Kamil Jonak
Journal:  Front Neuroinform       Date:  2021-12-14       Impact factor: 4.081

Review 4.  Improving Knowledge on Pathways to Functional Outcome in Schizophrenia: Main Results From the Italian Network for Research on Psychoses.

Authors:  Luigi Giuliani; Giulia Maria Giordano; Paola Bucci; Pasquale Pezzella; Francesco Brando; Silvana Galderisi
Journal:  Front Psychiatry       Date:  2021-12-14       Impact factor: 4.157

5.  Investigating the Relationship between White Matter Connectivity and Motivational Circuits in Subjects with Deficit Schizophrenia: A Diffusion Tensor Imaging (DTI) Study.

Authors:  Giulia M Giordano; Pasquale Pezzella; Mario Quarantelli; Paola Bucci; Anna Prinster; Andrea Soricelli; Andrea Perrottelli; Luigi Giuliani; Michele Fabrazzo; Silvana Galderisi
Journal:  J Clin Med       Date:  2021-12-23       Impact factor: 4.241

6.  Anticholinergic Burden and Cognitive Performance in Patients With Schizophrenia: A Systematic Literature Review.

Authors:  Rafaella Georgiou; Demetris Lamnisos; Konstantinos Giannakou
Journal:  Front Psychiatry       Date:  2021-12-28       Impact factor: 4.157

7.  We Should Improve Personalization of Management in Patients with a Diagnosis of Schizophrenia.

Authors:  Alfonso Tortorella
Journal:  J Clin Med       Date:  2021-12-30       Impact factor: 4.241

8.  Social Cognition Individualized Activities Lab for Social Cognition Training and Narrative Enhancement in Patients With Schizophrenia: A Randomized Controlled Study to Assess Efficacy and Generalization to Real-Life Functioning (Prot. n°: NCT05130853).

Authors:  Davide Palumbo; Edoardo Caporusso; Giuseppe Piegari; Claudio Mencacci; Sara Torriero; Luigi Giuliani; Michele Fabrazzo; Dario Pinto; Silvana Galderisi
Journal:  Front Psychiatry       Date:  2022-04-04       Impact factor: 4.157

9.  Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies.

Authors:  Amit Desai; Lauren Benner; Ruishan Wu; Lev Gertsik; Tolga Uz; Gerard J Marek; Tong Zhu
Journal:  Clin Pharmacokinet       Date:  2021-01       Impact factor: 6.447

10.  Investigating the Relationships of P3b with Negative Symptoms and Neurocognition in Subjects with Chronic Schizophrenia.

Authors:  Giulia M Giordano; Andrea Perrottelli; Armida Mucci; Giorgio Di Lorenzo; Mario Altamura; Antonello Bellomo; Roberto Brugnoli; Giulio Corrivetti; Paolo Girardi; Palmiero Monteleone; Cinzia Niolu; Silvana Galderisi; Mario Maj
Journal:  Brain Sci       Date:  2021-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.